I-Mab (IMAB) | Stock Price, Analysis, News, Fundaments & Technical Information

stock

I-Mab

NASDAQ | IMAB

0.74

USD

-0.0387 (-4.97%)

AT CLOSE (AS OF Apr 3, 2025)

$86M

MARKET CAP

P/E Ratio

-2.16

EPS

52 Week High

$0.76

52 Week Low

LIFE SCIENCES

Sector

IMAB Chart

Area

Trade Smarter

Take control of your trading journey with a set of smart tools for serious trades

Backtests

Strategy Backtester designed to automate your backtesting and revolutionize the way you trade

Learn More About Backtests

Scanner

Leverage the power of AI to detect valuable opportunities and gain the most out of the markets.

Learn More About Scanner

Signals

Automate your trading workflow with AI-powered trading signals to execute trades automatically.

Learn More About Signals

Journal

Record your trades and performance to improve your trading with AfterPullback’s Trading Journal

Learn More About Journal

IMAB Technicals

Tags:

IMAB Earnings

Yearly Income Statement (As of Dec 31, 2023)

Field	Value (CNY)
Gross Profit	$28M
Total Revenue	$28M
Cost Of Revenue	$0
Costof Goods And Services Sold	$0
Operating Income	-$1.2B
Selling General And Administrative	$64M
Research And Development	$114M
Operating Expenses	$201M
Investment Income Net	-
Net Interest Income	$51M
Interest Income	$52M
Interest Expense	$102K
Non Interest Income	-
Other Non Operating Income	-
Depreciation	-
Depreciation And Amortization	$24M
Income Before Tax	-$1.5B
Income Tax Expense	-$1.3B
Interest And Debt Expense	-
Net Income From Continuing Operations	-$1.5B
Comprehensive Income Net Of Tax	-
Ebit	-$1.2B
Ebitda	-$1.2B
Net Income	-$1.5B

Revenue & Profitability

Earnings Performance

IMAB Financials

Highlights

Balance Sheet

Cash Flow

Income Statement

Yearly

Quarterly

yearly Balance Sheet (As of Dec 31, 2023)

Field	Value (CNY)
Total Assets	$2.6B
Total Current Assets	$2.3B
Cash And Cash Equivalents At Carrying Value	$302M
Cash And Short Term Investments	$302M
Inventory	$13M
Current Net Receivables	-
Total Non Current Assets	$276M
Property Plant Equipment	-
Accumulated Depreciation Amortization Ppe	-
Intangible Assets	$17M
Intangible Assets Excluding Goodwill	$17M
Goodwill	$101M
Investments	-
Long Term Investments	$12M
Short Term Investments	$20M
Other Current Assets	$32M
Other Non Current Assets	-
Total Liabilities	$895M
Total Current Liabilities	$412M
Current Accounts Payable	-
Deferred Revenue	-
Current Debt	-
Short Term Debt	$7.3M
Total Non Current Liabilities	$483M
Capital Lease Obligations	$45M
Long Term Debt	$59M
Current Long Term Debt	$30M
Long Term Debt Noncurrent	-
Short Long Term Debt Total	$19M
Other Current Liabilities	$403M
Other Non Current Liabilities	-
Total Shareholder Equity	$1.7B
Treasury Stock	-
Retained Earnings	-$8.3B
Common Stock	$19K
Common Stock Shares Outstanding	$191M

yearly Cash Flow (As of Dec 31, 2023)

Field	Value (CNY)
Operating Cashflow	-$1.3B
Payments For Operating Activities	-
Proceeds From Operating Activities	-
Change In Operating Liabilities	-
Change In Operating Assets	-
Depreciation Depletion And Amortization	$7.4M
Capital Expenditures	$1.6M
Change In Receivables	-
Change In Inventory	$0
Profit Loss	-
Cashflow From Investment	-
Cashflow From Financing	$7.6M
Proceeds From Repayments Of Short Term Debt	-
Payments For Repurchase Of Common Stock	-
Payments For Repurchase Of Equity	-
Payments For Repurchase Of Preferred Stock	-
Dividend Payout	-
Dividend Payout Common Stock	-
Dividend Payout Preferred Stock	-
Proceeds From Issuance Of Common Stock	-
Proceeds From Issuance Of Long Term Debt And Capital Securities Net	-
Proceeds From Issuance Of Preferred Stock	-
Proceeds From Repurchase Of Equity	-$9.2M
Proceeds From Sale Of Treasury Stock	-
Change In Cash And Cash Equivalents	-
Change In Exchange Rate	-
Net Income	-$207M

yearly Income Statement (As of Dec 31, 2023)

Field	Value (CNY)
Gross Profit	$28M
Total Revenue	$28M
Cost Of Revenue	$0
Costof Goods And Services Sold	$0
Operating Income	-$1.2B
Selling General And Administrative	$64M
Research And Development	$114M
Operating Expenses	$201M
Investment Income Net	-
Net Interest Income	$51M
Interest Income	$52M
Interest Expense	$102K
Non Interest Income	-
Other Non Operating Income	-
Depreciation	-
Depreciation And Amortization	$24M
Income Before Tax	-$1.5B
Income Tax Expense	-$1.3B
Interest And Debt Expense	-
Net Income From Continuing Operations	-$1.5B
Comprehensive Income Net Of Tax	-
Ebit	-$1.2B
Ebitda	-$1.2B
Net Income	-$1.5B

IMAB Profile

I-Mab Profile

Sector: LIFE SCIENCES

Industry: PHARMACEUTICAL PREPARATIONS

I-Mab, a clinical-stage biopharmaceutical company, discovers, develops and markets biologics to treat cancer and autoimmune disorders. The company is headquartered in Shanghai, the People's Republic of China.

Most Active

Symbol	Price	Change %	Market Cap	Volume
DMN	$0.02	13.04%	-	706,860,781
NVDA	$103.14	-6.59%	$2.68T	263,349,217
LCID	$2.34	-2.30%	$7.67B	187,389,814
F	$9.68	-4.68%	$39.53B	173,285,336
PTIX	$0.43	91.50%	$4.04M	173,208,693

See more →

Symbol	Price	Change %	Market Cap	Volume
JNJ	$160.56	3.35%	$399.65B	9,908,361
PG	$172.76	1.92%	$399.61B	6,083,153
ABBV	$202.45	-1.34%	$364.89B	5,252,004
NVO	$67.60	-0.95%	$308.32B	7,033,051
AZN	$74.03	2.50%	$225.70B	6,150,517

See more →

Top Gainers

Symbol	Price	Change %	Market Cap	Volume
VCIG	$6.06	1,818.33%	$26.40M	302,396
MKTW	$9.19	1,684.81%	$19.91M	117,875
ICCT	$4.38	111.59%	$9.78M	168,784,937
PTIX	$0.43	91.50%	$4.04M	173,208,693
MRM	$0.65	74.84%	$2.91M	51,693,935

See more →

Top Losers

Symbol	Price	Change %	Market Cap	Volume
ALDX	$1.42	-73.33%	$326.91M	20,249,631
RFAC	$2.70	-68.60%	$8.44M	605,339
PKBO	$0.02	-67.86%	$531.87K	66,140
TCBP	$0.50	-67.53%	$360.37K	1,955,586
OMQS	$0.04	-66.36%	$1.50M	950,669